112 - Hot Topics in Medical Mycology

Tuesday, October 21, 2025

10:30 AM - 11:45 AM US ET

Location: Thomas B. Murphy Ballroom 2-3

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

SH

Sarah Hammond, MD (she/her/hers)

Director of Hematology/Oncology Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Boston, MA, United States
Cesar Berto, MD

Assistant Professor
University of Alabama at Birmingham, AL, United States

Faculty(s)

Felix Bongomin (he/him/his)

Lecturer
Gulu University, Uganda, Gulu, Uganda
Miranda So, PharmD MPH (she/her/hers)

Manager, Antimicrobial Stewardship Program
University Health Network
Mississauga, ON, Canada
Dallas Smith, PharmD, MAS (he/him/his)

Epidemiologist
Mycotic Diseases Branch, Centers for Disease Control and Prevention
Atlanta, Georgia, United States

Disclosure(s):

Sarah P. Hammond, MD: Cidara: Grant/Research Support; F2G: Grant/Research Support; GSK: Grant/Research Support; Melinta: Advisor/Consultant; Mundipharma: Grant/Research Support; Pfizer: Advisor/Consultant; Roche: Advisor/Consultant; Scynexis: Grant/Research Support; Seres Therapeutics: Advisor/Consultant; Takeda: Advisor/Consultant; Treeline Biotherapeutics: Advisor/Consultant

Cesar G. Berto, MD: Basilea Pharmaceutica: Grant/Research Support; Cidara Therapeutics: Grant/Research Support

Felix Bongomin: No financial relationships to disclose.

Miranda So, PharmD MPH: No financial relationships to disclose.

Dallas J. Smith, PharmD, MAS: No financial relationships to disclose.

Learning Objectives:

At the conclusion of this session, participants will be able to:

discuss the role of molecular and microbiological diagnostics in defining agents of fungal outbreaks;
discuss evidence-based use of therapeutic drug monitoring for azole antifungals and distinguish with which agents and which clinical scenarios (treatment vs. prophylaxis) this may be best deployed;
outline some of the major determinants of disparities in the burden and outcomes of fungal infections internationally.

Presentations:

10:30 AM - 10:55 AM US ET

Fungal Outbreaks: Lessons Learned
Speaker: Dallas J. Smith, PharmD, MAS (he/him/his) – Mycotic Diseases Branch, Centers for Disease Control and Prevention
10:55 AM - 11:20 AM US ET

The Role of Azole Therapeutic Drug Monitoring in the Treatment of Fungal Infections
Speaker: Miranda So, PharmD MPH (she/her/hers) – University Health Network
11:20 AM - 11:45 AM US ET

Health Disparities and the Global Burden of Fungal Infections: Bridging the Gap
Speaker: Felix Bongomin (he/him/his) – Gulu University, Uganda